Ambulatory Blood Pressure Parameters Among Men With Hypogonadism Treated With Testosterone Transdermal Therapy
Authors' conclusion
A meaningful effect of 16-week TTS treatment on 24-hour average SBP among men with hypogonadism could not be ruled out based on the study's noninferiority criterion. The magnitude of mean changes observed may not be clinically meaningful regarding cardiovascular events.
Study context
- Population
- Men (mean age 56.2 years) with hypogonadism not receiving testosterone replacement therapy in the past 6 months, 41 US sites62 analysed
- Participants
- 168 men
- Outcome
- Mean change from baseline in 24-hour SBP (24-hour ambulatory blood pressure (BP) monitoring)
- Follow-up
- Week 16
Methodological detailsnoninferiority, multicentre
- Noninferiority
- Multicentre
Main finding
As reported in the abstract
Mean change from baseline in 24-hour average SBP
Mean change from baseline to week 16 in 24-hour average systolic BP (SBP)
3.5 mmHg
95% CI 1.2–5.8 mmHg; n = 62
Further findings
SBP change by time of day and hypertension subgroup · week 16
- Mean changes larger at daytime vs nighttime and in men with vs without hypertension
Safety
- Cardiovascular adverse events, rare and nonserious
- <2%
- Major cardiovascular adverse events
- 0
Original publication
Ambulatory Blood Pressure Parameters Among Men With Hypogonadism Treated With Testosterone Transdermal Therapy. Endocr Pract. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →